Sun Pharma slides 6% but Motilal Oswal recommends Buy: 3 reasons why
Sun Pharmaceutical Industries shares fell 5.7% on the NSE after weak Q1 FY26 results. Motilal Oswal maintains 'Buy' call with a target price of Rs 1,960, expecting 14% earnings growth. Consolidated net profit fell 20% year-over-year, but revenue rose over 9%. EBITDA increased by 19.2% and margin expanded by 250 basis points. Share price has declined in the past month.